Fenton et al. developed mAb 225.28, a monoclonal antibody targeting NG2, to study NG2 expression on blasts in newly diagnosed AML patients and its association with cytogenetic abnormalities and prognostic molecular markers [33]. The gene discussed is CSPG4; the disease is acute myeloid leukemia.